Here are the Power 100 leaders in tourism — who either lead an organization that is itself a major destination for visitors, or, in one instance, who oversee the area's hospitality efforts as a whole.

Power 100 2023: Tourism: James Holt, Zoe Kahr, Kevin Kane, Joel Weinshanker, Russell Wigginton

The MIF Invests in Luminary Therapeutics, KAHR, and Telo Therapeutics to Accelerate Novel Therapies for the Treatment of Multiple Myeloma - themmrf.org

If there ever was a time for leadership, the pandemic era has been that occasion.

As a leader, what do you do when COVID-19 shuts down all live performances, from ballet to music to theater, and on to art museums and other cultural attractions?

The answer involved perseverance — rebuilding audiences and visitors and finding funding from local, state, and national sources to weather an unprecedented upending of an industry.

For Memphis Business Journal’s next group of Women Who Lead, honoring…

Women Who Lead: Zoe Kahr of the Memphis Brooks Museum of Art

Published: Nov 17, 2022
MODI'IN, Israel, and NORWALK, Conn., Nov. 17, 2022 /PRNewswire/ -- KAHR , a clinical-stage biotech company developing a novel, bi-specific CD47x4-1BB targeting immunotherapy that activates innate and adaptive immunity to treat solid tumors and blood cancers, and the Myeloma Investment Fund (MIF), the Multiple Myeloma Research Foundation's (MMRF) venture philanthropy subsidiary, today announced that the MIF has invested in KAHR to explore the potential of DSP107, KAHR's le

Myeloma Investment Fund Invests in KAHR to Explore Potential of KAHR's Lead Immunotherapy Drug Candidate for the Treatment of Multiple Myeloma

Photo/Shutterstock
KAHR, a clinical stage biotech company that is developing a treatment for solid tumors and blood cancers has received investment from the Myeloma Investment Fund (MIF). MIF has made the investment to explore the potential of DSP107, KAHR’s leading immunotherapy drug candidate for the treatment of multiple myeloma . “We are thrilled to partner with KAHR to help advance DSP107 as a potential drug candidate for multiple myeloma,” said Peter Kosa, managing director of MIF. “This investment reinforces our commitment to drive the development of the most innovative treatment approaches for myeloma patients.”
MIF investment to explore potential
Yaron Pereg, CEO of KAHR, added “We are excited to have the Myeloma Investment Fund join our syndicate of investors. This vote of confidence helps us advance the clinical development of our lead product candidate, DSP107, which is being tested in multiple clinical studies for the benefit of patients who are non-responsive or refractory to existing therapies.”
Together with the current investment, KAHR has raised a total of $59 million since June 2021 in private placements supported by aMoon Fund, Flerie Invest AB, Peregrine Ventures, BVF Partners LP, DAFNA Capital Management LLC, Consensus Business Group, Hadasit Bio Holdings Ltd (HBL), Mirae Asset, Shavit Capital, Pavilion Capital, Cancer Focus Fund and Remedii. Content continues below
Related Content
DSP107 is a dual-targeting fusion protein that activates innate and adaptive immunity by blocking CD47 on cancer cells and utilizing 4-1BB conditional co-stimulatory activation of T-cells. By binding both cancer cells and immune cells, DSP107 combines checkpoint inhibition with tumor localized immune cell activation to bolster anti-tumor immunity. Targeted macrophage
DSP107 binds to and inhibits CD47, an immune checkpoint protein overexpressed in many cancers that enables the tumor to evade immune recognition and attack by macrophages. Simultaneously, when anchored to the tumor, DSP107 binds 4-1BB, a co-stimulatory receptor expressed on T-cells, recruits them to the tumor microenvironment and stimulates their activation. These activities result in targeted macrophage and T-cell mediated immune activation and tumor destruction. DSP107 has demonstrated an excellent safety profile, no binding to red blood cells, biological activity, and high disease control rates in a phase 1 trial of patients with advanced solid tumors. DSP107 is also being tested in combination with Atezolizumab in a phase 1/2 trial in patients with advanced solid tumors and in combination with standard of care therapies for relapsed/refractory AML and MDS patients in a phase 1b study. DSP107, is a CD47x41BB targeting compound. DSP107 is being tested in a phase 1/2 clinical trial in advanced solid tumors and a phase 1b clinical trial in blood cancers. KAHR’s preclinical pipeline includes DSP502, a PVRxPD-L1 targeting fusion protein, and DSP216, an HLA-GxCD47 targeting fusion protein. MIF venture philanthropy
MIF is a subsidiary of the Multiple Myeloma Research Foundation (MMRF), which seeks to find a cure for all multiple myeloma patients by relentlessly pursuing innovations that accelerate the development of personalized treatments for cancer. MIF is a venture philanthropy fund that invests in promising companies, clinical assets, and technologies in oncology to drive the development of new therapies for multiple myeloma. Content continues below
Related Content
It collaborates closely with portfolio companies to help them advance multiple myeloma research. This evergreen fund is supported entirely by philanthropy; all profits will be reinvested back into research for more effective treatments until there is a cure for every patient. Explore Related Topics:

MIF invests in KAHR to explore lead immunotherapy drug for multiple myeloma

Samsung BioLogics (KRX: 207940.KS) is a Contract Manufacturing Organization (CMO) committed to quality-driven manufacturing of biopharmaceutical products. It will provide the infrastructure for partnerships with industry players to develop, refine, and distribute biopharmaceutical products worldwide.

Samsung BioLogics

Samsung Biologics , South Korea 's leading contract development and manufacturing organization , has signed a CDMO deal with KAHR Medical , an Israeli cancer immunotherapy company , furthering its market expansion beyond America and Europe into the Middle East .

Samsung Biologics inks CDMO deal with Israel-based KAHR Medical2021.06.03 11:02

Cobra Biologics is an international contract manufacturing organization (CMO) of biologics and pharmaceuticals for clinical and commercial supply. On November 5, 2019, Cobra Biologics was acquired by Cognate BioServices, terms of the agreement were not disclosed.

Cobra Biologics

KAHR

Cellect Biotechnology

BioLineRx

GluSense

Genentech

Weizmann Institute of Science

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

Cancer

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Biopharma Tech

Unattributed VC - II

Series A - II

Series A

Seed - II

Seed

Series A - III

Series C

Series D

Series B

KAHR develops a drug platform of immunotherapeutic bi-functional fusion proteins that harness the human immune system to target multiple cancer indications. Its technology allows the construction of biological drugs with two functional sides that allow these drugs to block or activate two reinforcing biological signals at the same time. KAHR's DSP platforms, named DSP-Hexamers and DSP-Clusters, form a new generation of biological drugs for the treatment of multiple cancer and autoimmune disease indications. The company was founded in 2005 and is based in Jerusalem, Israel.

Wells Fargo Success Story

Professional Services

Platform Overview

KAHR

Compete with KAHR?

Compete with KAHR?

Discover the right solution for your team